Abstract
14-3-3 is a class of proteins able to interact with a multitude of targets by establishing protein-protein interactions (PPIs). They are usually found in all eukaryotes with a conserved secondary structure and high sequence homology among species. 14-3-3 proteins are involved in many physiological and pathological cellular processes either by triggering or interfering with the activity of specific protein partners. In the last years, the scientific community has collected many evidences on the role played by seven human 14-3-3 isoforms in cancer or neurodegenerative diseases. Indeed, these proteins regulate the molecular mechanisms associated to these diseases by interacting with (i) oncogenic and (ii) pro-apoptotic proteins and (iii) with proteins involved in Parkinson and Alzheimer diseases. The discovery of small molecule modulators of 14-3-3 PPIs could facilitate complete understanding of the physiological role of these proteins, and might offer valuable therapeutic approaches for these critical pathological states.
Keywords: 14-3-3, cancer, neurodegeneration, protein-protein interaction, small molecules, drug discovery, phosphorylation.
Current Medicinal Chemistry
Title:Structure, Function, Involvement in Diseases and Targeting of 14-3-3 Proteins: An Update
Volume: 25 Issue: 1
Author(s): Ylenia Cau, Daniela Valensin, Mattia Mori, Sara Draghi and Maurizio Botta*
Affiliation:
- Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via A. Moro 2, Siena,Italy
Keywords: 14-3-3, cancer, neurodegeneration, protein-protein interaction, small molecules, drug discovery, phosphorylation.
Abstract: 14-3-3 is a class of proteins able to interact with a multitude of targets by establishing protein-protein interactions (PPIs). They are usually found in all eukaryotes with a conserved secondary structure and high sequence homology among species. 14-3-3 proteins are involved in many physiological and pathological cellular processes either by triggering or interfering with the activity of specific protein partners. In the last years, the scientific community has collected many evidences on the role played by seven human 14-3-3 isoforms in cancer or neurodegenerative diseases. Indeed, these proteins regulate the molecular mechanisms associated to these diseases by interacting with (i) oncogenic and (ii) pro-apoptotic proteins and (iii) with proteins involved in Parkinson and Alzheimer diseases. The discovery of small molecule modulators of 14-3-3 PPIs could facilitate complete understanding of the physiological role of these proteins, and might offer valuable therapeutic approaches for these critical pathological states.
Export Options
About this article
Cite this article as:
Cau Ylenia , Valensin Daniela , Mori Mattia, Draghi Sara and Botta Maurizio *, Structure, Function, Involvement in Diseases and Targeting of 14-3-3 Proteins: An Update, Current Medicinal Chemistry 2018; 25 (1) . https://dx.doi.org/10.2174/0929867324666170426095015
DOI https://dx.doi.org/10.2174/0929867324666170426095015 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy
Current Pharmaceutical Design Validation of Human Clinical Genetic Tests
Mini-Reviews in Medicinal Chemistry Clinical Pharmacology of Novel Selective COX-2 Inhibitors
Current Pharmaceutical Design IGF Signaling Pathway as a Selective Target of Familial Breast Cancer Therapy
Current Molecular Medicine IL-6 Signaling and its Blockade with a Humanized Anti-Interleukin-6 Receptor Antibody in Rheumatoid Arthritis: Advent of a New and Innovative Therapeutic Drug, Tocilizumab
Current Rheumatology Reviews Secondary Radiation-Induced Bone Tumours Demonstrate a High Degree of Genomic Instability Predictive of a Poor Prognosis
Current Genomics Profiling of Autophagy-Associated microRNAs in the Osteosarcoma Cell Line of U2OS
Anti-Cancer Agents in Medicinal Chemistry Phosphodiesterase Inhibitors as Therapeutics for Traumatic Brain Injury
Current Pharmaceutical Design Immune Cells Act as Promising Targets for the Treatment of Bone Metastasis
Recent Patents on Anti-Cancer Drug Discovery Microemulsions for Colorectal Cancer Treatments. General Considerations and Formulation of Methotrexate
Mini-Reviews in Medicinal Chemistry Gemini Analogs of Vitamin D
Current Topics in Medicinal Chemistry Carbohydrate-Dependent Defense Mechanisms Against Helicobacter pylori Infection
Current Drug Metabolism Biotherapy for Autoimmune Liver Diseases
Current Pharmaceutical Biotechnology Design, Synthesis and Anticancer Evaluation of Carbazole Fused Aminopyrimidine Derivatives
Letters in Organic Chemistry Mitophagy in Carcinogenesis and Tumour Progression- A New Paradigm with Emerging Importance
Anti-Cancer Agents in Medicinal Chemistry Pharmacoepigenomics: An Interplay of Epigenetic Modulation of Drug Response and Modulation of the Epigenome by Drugs
Current Pharmaceutical Design Bisphosphonates in the Prevention of Disease Recurrence: Current Results and Ongoing Trials
Current Cancer Drug Targets A Review on Mechanisms of Anti Tumor Activity of Chalcones
Anti-Cancer Agents in Medicinal Chemistry Metabolic Remodeling Induced by Adipocytes: A New Achilles' Heel in Invasive Breast Cancer?
Current Medicinal Chemistry Recent Development of Small Molecule Glutaminase Inhibitors
Current Topics in Medicinal Chemistry